Health
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
WILMINGTON, Del., September 24, 2025--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/83356d005ffb801f37921354a2953cf4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UW7w31BhstAPb5lNvnrYdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/83356d005ffb801f37921354a2953cf4","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qn7zE6TgLiIirFaCOFN6eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/83356d005ffb801f37921354a2953cf4","width":1181,"height":286}},"lazy":false},{"type":"text","content":"Based on DESTINY-Breast09 Phase III trial results which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of greater than three years","length":218,"tagName":"p","attribs":{}},{"type":"text","content":"If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU-based treatment approach would move into the 1st-line HER2-positive metastatic setting with potential to become a new standard of care","length":188,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., September 24, 2025--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.","length":377,"tagName":"p"},{"type":"text","content":"The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the first quarter of 2026.","length":434,"tagName":"p"},{"type":"text","content":"ENHERTU was also recently granted Breakthrough Therapy Designation (BTD) by the FDA in this setting. BTD accelerates the development and regulatory review of p...